Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Cancer Res. 2015 May 22;75(15):3167–3180. doi: 10.1158/0008-5472.CAN-14-3701

Figure 6. Inhibition of BRAFV600E/INK4A-ARFNull lung cancer cell growth by either MEK or MDM2 inhibition.

Figure 6

A. BRAFV600E/INK4A-ARFNull (BIA) lung cancer cells were treated with vehicle, nutlin-3a, MEK1/2 inhibitor (PD325901, PD) or the combination with cell proliferation assessed by staining with Crystal Violet or cell counting. A 2-sided t-test was performed to assess significance (* indicates p <0.001). All three conditions are significant versus vehicle, as well as combination treatment vs single agent.

B. BIA lung cancer cells were treated with vehicle, nutlin-3a, MEK1/2 inhibitor (PD) or the combination with transit through S phase of the cell division cycle assessed by labeling with BrdU. BrdU incorporation and position in the cell cycle after 24 hours of drug treatment was assessed by co-staining with an anti-BrdU antisera and propidium iodide and then detected by iF and flow cytometry.

C. Immunoblot analysis of BIA lung cancer cells treated with vehicle, nutlin-3a, MEK1/2 inhibitor (PD) or the combination as indicated.